Hyphens Pharma
↗Singapore, Singapore
Hyphens Pharma International Limited is a leading specialty pharmaceutical and consumer healthcare group based in Singapore with a strong presence across ASEAN countries, including the Philippines. The company focuses on the sales and marketing of specialty pharmaceutical products, proprietary dermatological brands (such as Ceradan and TDF), and health supplements (Ocean Health).
They operate through a business model that leverages exclusive distributorship and licensing agreements with brand principals from Europe and the United States. The company has recently pivoted to include medical aesthetics as a core growth pillar, alongside its established dermatology and specialty pharmaceutical segments.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Specialty Pharmaceuticals and Consumer Healthcare
SIZE & FINANCIALS
Employees:501-1000
Revenue:$100M-$500M
Founded:1998
Ownership:public
Status:operating
STOCK
Exchange:Singapore Exchange (SGX)
Ticker:1J5
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule, Topical agents
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Ardence Pharma, Novem
Key Partnerships:Cosmo Pharmaceuticals (Winlevi licensing), Louis Widmer SA
COMPETITION
Position:Leader
LEADERSHIP
Key Executives:
Lim See Wah - Executive Chairman and CEO
LINKS
Website:hyphens.com.ph
LinkedIn:LinkedIn Profile
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Hyphens Pharma and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Hyphens Pharma. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.